281 related articles for article (PubMed ID: 21076522)
1. Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.
Nesbeth Y; Conejo-Garcia JR
Clin Dev Immunol; 2010; 2010():139304. PubMed ID: 21076522
[TBL] [Abstract][Full Text] [Related]
2. Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts.
Perez C; Jukica A; Listopad JJ; Anders K; Kühl AA; Loddenkemper C; Blankenstein T; Charo J
Int J Cancer; 2015 Jul; 137(2):359-71. PubMed ID: 25530110
[TBL] [Abstract][Full Text] [Related]
3. Are Conventional Type 1 Dendritic Cells Critical for Protective Antitumor Immunity and How?
Cancel JC; Crozat K; Dalod M; Mattiuz R
Front Immunol; 2019; 10():9. PubMed ID: 30809220
[TBL] [Abstract][Full Text] [Related]
4. CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion.
Nesbeth Y; Scarlett U; Cubillos-Ruiz J; Martinez D; Engle X; Turk MJ; Conejo-Garcia JR
Cancer Res; 2009 Aug; 69(15):6331-8. PubMed ID: 19602595
[TBL] [Abstract][Full Text] [Related]
5. Engineering T cells for adoptive therapy: outsmarting the tumor.
Kunert A; Debets R
Curr Opin Immunol; 2018 Apr; 51():133-139. PubMed ID: 29579622
[TBL] [Abstract][Full Text] [Related]
6. To Remember or to Forget: The Role of Good and Bad Memories in Adoptive T Cell Therapy for Tumors.
Mondino A; Manzo T
Front Immunol; 2020; 11():1915. PubMed ID: 32973794
[TBL] [Abstract][Full Text] [Related]
7. Optimizing T-cell expansion: have we reached the limit?
Melenhorst JJ
Cytotherapy; 2009; 11(7):813-4. PubMed ID: 19903094
[No Abstract] [Full Text] [Related]
8. Adoptive T cell therapy of cancer.
Brenner MK; Heslop HE
Curr Opin Immunol; 2010 Apr; 22(2):251-7. PubMed ID: 20171074
[TBL] [Abstract][Full Text] [Related]
9. Adoptive T cell therapy: points to consider.
Yee C
Curr Opin Immunol; 2018 Apr; 51():197-203. PubMed ID: 29730057
[TBL] [Abstract][Full Text] [Related]
10. Considerations on clinical use of T cell immunotherapy for cancer.
Plautz GE; Cohen PA; Shu S
Arch Immunol Ther Exp (Warsz); 2003; 51(4):245-57. PubMed ID: 12956434
[TBL] [Abstract][Full Text] [Related]
11. Adoptive T-cell immunotherapy of cancer.
Li Q; Chang AE
Cytokines Cell Mol Ther; 1999 Jun; 5(2):105-17. PubMed ID: 10515683
[TBL] [Abstract][Full Text] [Related]
12. CDR3δ -grafted γ9δ2T cells mediate effective antitumor reactivity.
Zhao H; Xi X; Cui L; He W
Cell Mol Immunol; 2012 Mar; 9(2):147-54. PubMed ID: 21909128
[TBL] [Abstract][Full Text] [Related]
13. Enhancing adoptive CD8 T cell therapy by systemic delivery of tumor associated antigens.
Jæhger DE; Hübbe ML; Kræmer MK; Clergeaud G; Olsen AV; Stavnsbjerg C; Wiinholt MN; Kjær A; Henriksen JR; Hansen AE; Andresen TL
Sci Rep; 2021 Oct; 11(1):19794. PubMed ID: 34611284
[TBL] [Abstract][Full Text] [Related]
14. [Mechanisms of resistance and escape to CAR-T cells].
Grinda T; Brouard J; Tran D; Rubio MT
Bull Cancer; 2021 Oct; 108(10S):S128-S140. PubMed ID: 34920795
[TBL] [Abstract][Full Text] [Related]
15. A Critical Role of CD40 and CD70 Signaling in Conventional Type 1 Dendritic Cells in Expansion and Antitumor Efficacy of Adoptively Transferred Tumor-Specific T Cells.
Oba T; Hoki T; Yamauchi T; Keler T; Marsh HC; Cao X; Ito F
J Immunol; 2020 Oct; 205(7):1867-1877. PubMed ID: 32848036
[TBL] [Abstract][Full Text] [Related]
16. Adoptive cellular therapy with T cells expressing the dendritic cell growth factor Flt3L drives epitope spreading and antitumor immunity.
Lai J; Mardiana S; House IG; Sek K; Henderson MA; Giuffrida L; Chen AXY; Todd KL; Petley EV; Chan JD; Carrington EM; Lew AM; Solomon BJ; Trapani JA; Kedzierska K; Evrard M; Vervoort SJ; Waithman J; Darcy PK; Beavis PA
Nat Immunol; 2020 Aug; 21(8):914-926. PubMed ID: 32424363
[TBL] [Abstract][Full Text] [Related]
17. Conditioning treatment with CD27 Ab enhances expansion and antitumor activity of adoptively transferred T cells in mice.
Wasiuk A; Weidlick J; Sisson C; Widger J; Crocker A; Vitale L; Marsh HC; Keler T; He LZ
Cancer Immunol Immunother; 2022 Jan; 71(1):97-109. PubMed ID: 34028568
[TBL] [Abstract][Full Text] [Related]
18. Human effector T cells derived from central memory cells rather than CD8(+)T cells modified by tumor-specific TCR gene transfer possess superior traits for adoptive immunotherapy.
Wu F; Zhang W; Shao H; Bo H; Shen H; Li J; Liu Y; Wang T; Ma W; Huang S
Cancer Lett; 2013 Oct; 339(2):195-207. PubMed ID: 23791878
[TBL] [Abstract][Full Text] [Related]
19. Phenotype, functions and fate of adoptively transferred tumor draining lymphocytes activated ex vivo in mice with an aggressive weakly immunogenic mammary carcinoma.
Miller CH; Graham L; Bear HD
BMC Immunol; 2010 Nov; 11():54. PubMed ID: 21050466
[TBL] [Abstract][Full Text] [Related]
20. [Antitumor immunity and cellular cancer therapies].
Catros-Quemener V; Bouet F; Genetet N
Med Sci (Paris); 2003 Jan; 19(1):43-53. PubMed ID: 12836191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
